{"id":745179,"date":"2015-06-03T16:00:00","date_gmt":"2015-06-03T16:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-investigational-improve-it-study-of-vytorin-ezetimibe-and-simvastatin-published-in-the-new-england-journal-of-medicine\/"},"modified":"2025-11-07T01:25:07","modified_gmt":"2025-11-07T06:25:07","slug":"results-from-investigational-improve-it-study-of-vytorin-ezetimibe-and-simvastatin-published-in-the-new-england-journal-of-medicine","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-investigational-improve-it-study-of-vytorin-ezetimibe-and-simvastatin-published-in-the-new-england-journal-of-medicine\/","title":{"rendered":"Results from Investigational IMPROVE-IT Study of VYTORIN\u00ae (ezetimibe and simvastatin) Published in the New England Journal of Medicine"},"content":{"rendered":"<p>\n      Merck (NYSE: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.dailyfinance.com%2Fquotes%2FMRK%2Fusa&amp;esheet=51115074&amp;newsitemid=20150603005091&amp;lan=en-US&amp;anchor=MRK&amp;index=1&amp;md5=b02dcbb9b1a9ee32a53457e95d9b7e21\" rel=\"nofollow\">MRK<\/a>),<br \/>\n      known as MSD outside the United States and Canada, today announced that<br \/>\n      the<i> New England Journal of Medicine <\/i>published<i> <\/i>the results<br \/>\n      of the IMPROVE-IT trial, an investigational study comparing treatment<br \/>\n      with VYTORIN<sup>\u00ae<\/sup> (ezetimibe and simvastatin) to treatment with<br \/>\n      simvastatin alone in more than 18,000 patients presenting with acute<br \/>\n      coronary syndromes.\n    <\/p>\n<p>\n      The <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fprescription-medicine-news%2Fvytorin-ezetimibesimvastatin-significantly-reduced-cardiovas&amp;esheet=51115074&amp;newsitemid=20150603005091&amp;lan=en-US&amp;anchor=results&amp;index=2&amp;md5=6dc760ef0a19140b18545d285989c692\" rel=\"nofollow\">results<\/a><br \/>\n      of IMPROVE-IT were first presented at the American Heart Association<br \/>\n      Scientific Sessions in November, 2014. In IMPROVE-IT, patients taking<br \/>\n      the LDL-cholesterol-lowering medicine VYTORIN\u2014 which combines<br \/>\n      simvastatin with the non-statin ZETIA<sup>\u00ae<\/sup><br \/>\n      (ezetimibe)\u2014experienced significantly fewer major cardiovascular events<br \/>\n      (as measured by a composite of cardiovascular death, non-fatal<br \/>\n      myocardial infarction, non-fatal stroke, re-hospitalization for unstable<br \/>\n      angina or coronary revascularization occurring at least 30 days after<br \/>\n      randomization) than patients treated with simvastatin alone.\n    <\/p>\n<p>\n      \u201cIMPROVE-IT was designed to answer a very important scientific question<br \/>\n      about the relationship between cardiovascular risk and lowering LDL-C to<br \/>\n      very low levels with ezetimibe in combination with a statin, and we are<br \/>\n      pleased that the results are now being published in NEJM,\u201d said Eugene<br \/>\n      Braunwald, M.D., study co-chair, founding chair of the TIMI Study Group<br \/>\n      at Brigham and Women&#8217;s Hospital. \u201cWe are very grateful to our<br \/>\n      investigators and to the participating patients for their commitment to<br \/>\n      completion of this complex, nine-year study. The analyses of the 18,000<br \/>\n      patient IMPROVE-IT study are a robust addition to the many other<br \/>\n      important studies on the importance of lowering LDL-C.\u201d\n    <\/p>\n<p>\n      VYTORIN and ZETIA are currently indicated for use along with a healthy<br \/>\n      diet to reduce elevated LDL cholesterol in patients with hyperlipidemia.<br \/>\n      The current U.S. Prescribing Information for both products states that<br \/>\n      the effect of ezetimibe on cardiovascular morbidity and mortality, alone<br \/>\n      or incremental to statin therapy, has not been determined. Merck has<br \/>\n      submitted the data from the IMPROVE-IT study to the U.S. Food and Drug<br \/>\n      Administration to support a new indication for reduction of<br \/>\n      cardiovascular events for ZETIA (ezetimibe) and VYTORIN (ezetimibe and<br \/>\n      simvastatin).\n    <\/p>\n<p>\n      In November 2014, Merck announced IMPROVE-IT met its primary and all<br \/>\n      secondary composite efficacy endpoints. In IMPROVE-IT, at seven years,<br \/>\n      32.7 percent of patients taking VYTORIN experienced a first primary<br \/>\n      endpoint event (major cardiovascular event) compared to 34.7 percent of<br \/>\n      patients taking simvastatin alone, corresponding to a 6.4% relative risk<br \/>\n      reduction (absolute risk reduction 2%, hazard ratio of 0.936, 95% CI<br \/>\n      0.887 to 0.988, p=0.016). The mean LDL-C in the study at one year was 53<br \/>\n      mg\/dl in the VYTORIN arm and 70 mg\/dl in the simvastatin arm.\n    <\/p>\n<p>\n      In a separate exploratory analysis of major vascular events, the risk<br \/>\n      reduction in the VYTORIN arm compared to the simvastatin alone arm was<br \/>\n      consistent with the treatment effect that had been projected based on<br \/>\n      prior studies of statins.\n    <\/p>\n<p>\n      There were no significant differences between treatment groups in<br \/>\n      adverse events of special interest, which included myopathy and<br \/>\n      rhabdomyolysis, gallbladder adverse events, liver enzyme elevations<br \/>\n      greater than or equal to three times the upper limit of normal (ULN) and<br \/>\n      cancer. These safety findings from IMPROVE-IT were generally consistent<br \/>\n      with current labeling for ezetimibe. Among 9,067 patients in the<br \/>\n      ezetimibe\/simvastatin group vs. 9,077 patients in the simvastatin group,<br \/>\n      myopathy was reported in 0.2 percent vs. 0.1 percent of patients,<br \/>\n      respectively; rhabdomyolysis was reported in 0.1 percent vs. 0.2<br \/>\n      percent; gallbladder-related adverse events were reported in 3.1 percent<br \/>\n      vs. 3.5 percent; cholecystectomy was reported in 1.5 percent vs. 1.5<br \/>\n      percent; and alanine aminotransferase (ALT) and\/or aspartate<br \/>\n      transaminase (AST) elevations (greater than or equal to three times ULN,<br \/>\n      consecutive) were reported in 2.5 percent vs. 2.3 percent of patients.<br \/>\n      Over seven years, new, relapsing or progressing cancer was reported in<br \/>\n      10.2 percent of patients in both treatment groups.\n    <\/p>\n<p>\n      VYTORIN should not be taken with strong CYP3A4 inhibitors (e.g.,<br \/>\n      itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease<br \/>\n      inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin,<br \/>\n      telithromycin, nefazodone, and cobicistat-containing products); or with<br \/>\n      gemfibrozil, cyclosporine, or danazol. VYTORIN also should not be taken<br \/>\n      by anyone with active liver disease, unexplained persistent elevations<br \/>\n      of hepatic transaminase levels, or hypersensitivity to the product; or<br \/>\n      by women who are pregnant, nursing or may become pregnant. ZETIA should<br \/>\n      not be taken by people with hypersensitivity to any component of the<br \/>\n      medication. Statin contraindications also apply when ZETIA is used with<br \/>\n      these drugs: statins are contraindicated in patients with active liver<br \/>\n      disease, unexplained persistent elevations in hepatic transaminase<br \/>\n      levels and in pregnant and nursing women. Refer to individual statin<br \/>\n      labels for details about who should not take that statin.\n    <\/p>\n<p>\n      <b>About the IMPROVE-IT Trial<\/b>\n    <\/p>\n<p>\n      IMPROVE-IT (IMProved Reduction of Outcomes: VYTORIN Efficacy<br \/>\n      International Trial) was led by the Thrombolysis In Myocardial<br \/>\n      Infarction (TIMI) Study Group of Brigham and Women\u2019s Hospital and the<br \/>\n      Duke Clinical Research Institute (DCRI), and was sponsored by Merck.<br \/>\n      IMPROVE-IT was an international, multi-center, randomized, double-blind<br \/>\n      active comparator trial of 18,144 high-risk patients presenting with<br \/>\n      acute coronary syndromes (ACS), including unstable angina (UA),<br \/>\n      non-ST-segment elevation acute myocardial infarction (NSTEMI), and<br \/>\n      ST-segment elevation acute myocardial infarction (STEMI). The study<br \/>\n      assessed the incidence of major CV events, as measured by a composite of<br \/>\n      CV death, non-fatal MI, non-fatal stroke, re-hospitalization for ACS, or<br \/>\n      coronary revascularization (occurring 30 days or more after the initial<br \/>\n      event), in patients treated with ezetimibe\/simvastatin (VYTORIN)<br \/>\n      compared with patients treated with simvastatin alone.\n    <\/p>\n<p>\n      All patients in the trial were started at doses of ezetimibe and<br \/>\n      simvastatin 10\/40 mg or simvastatin 40 mg. Prior to a 2011 protocol<br \/>\n      amendment, the dose could be titrated to ezetimibe\/simvastatin 10\/80 mg<br \/>\n      or simvastatin 80 mg if successive LDL-C values exceeded 79 mg\/dL. The<br \/>\n      study enrolled patients within 10 days of ACS hospitalization who had<br \/>\n      sufficient risk as defined in the protocol and who had an initial LDL-C<br \/>\n      of \u2264125 mg\/dL if lipid-lowering drug na\u00efve or &lt;100 mg\/dL if on a prior<br \/>\n      prescription lipid-lowering therapy identified as no more potent than<br \/>\n      simvastatin 40 mg\/day. The LDL-C entry limitations were designed to<br \/>\n      enroll patients reasonably anticipated to achieve LDL-C levels of 70<br \/>\n      mg\/dL or less in the simvastatin only cohort, which was the optional<br \/>\n      recommended target set in the 2004 update to the Adult Treatment Panel<br \/>\n      (ATP) III guidelines.\n    <\/p>\n<p>\n      <b>About VYTORIN\u00ae (ezetimibe and simvastatin)<\/b>\n    <\/p>\n<p>\n      VYTORIN contains ezetimibe and simvastatin. VYTORIN is indicated as<br \/>\n      adjunctive therapy to diet for the reduction of elevated total<br \/>\n      cholesterol, LDL cholesterol, apolipoprotein B, triglycerides, and<br \/>\n      non\u2013HDL cholesterol, and to increase HDL cholesterol in patients with<br \/>\n      primary (heterozygous familial and nonfamilial) hyperlipidemia or mixed<br \/>\n      hyperlipidemia when diet alone is not enough.\n    <\/p>\n<p>\n      The Prescribing Information for VYTORIN states that no incremental<br \/>\n      benefit of VYTORIN on cardiovascular morbidity and mortality over and<br \/>\n      above that demonstrated for simvastatin has been established. VYTORIN is<br \/>\n      not indicated to reduce cardiovascular events in patients who have<br \/>\n      presented with acute coronary syndromes.\n    <\/p>\n<p>\n      <b>Selected cautionary information about VYTORIN (ezetimibe and<br \/>\n      simvastatin)<\/b>\n    <\/p>\n<p>\n      All patients starting therapy with VYTORIN, or whose dose of VYTORIN is<br \/>\n      being increased, should be advised of the risk of myopathy, including<br \/>\n      rhabdomyolysis, and told to promptly report any unexplained muscle pain,<br \/>\n      tenderness, or weakness particularly if accompanied by malaise or fever<br \/>\n      or if muscle signs and symptoms persist after discontinuing VYTORIN.<br \/>\n      VYTORIN should be discontinued immediately if markedly elevated creatine<br \/>\n      kinase (CK) levels occur or myopathy is diagnosed or suspected. VYTORIN<br \/>\n      contains simvastatin, which occasionally causes myopathy manifested as<br \/>\n      muscle pain, tenderness, or weakness with CK levels above 10 times ULN.<br \/>\n      Myopathy sometimes takes the form of rhabdomyolysis with or without<br \/>\n      acute renal failure secondary to myoglobinuria, and rare fatalities have<br \/>\n      occurred. Predisposing factors for myopathy include advanced age (\u226565<br \/>\n      years), female gender, uncontrolled hypothyroidism, and renal<br \/>\n      impairment. The risk of myopathy, including rhabdomyolysis, is dose<br \/>\n      related.\n    <\/p>\n<p>\n      The 10\/80 mg dose of VYTORIN should not be started in new patients. The<br \/>\n      risk of myopathy, including rhabdomyolysis, is greater in patients<br \/>\n      taking simvastatin 80 mg compared with other statin therapies with<br \/>\n      similar or greater LDL cholesterol lowering efficacy, and with lower<br \/>\n      doses of simvastatin. The 10\/80 mg dose of VYTORIN should be used only<br \/>\n      in patients who have been taking that dose chronically (e.g., for 12<br \/>\n      months or more) without evidence of muscle toxicity. If a patient who is<br \/>\n      currently tolerating the 10\/80 mg dose needs to be initiated on an<br \/>\n      interacting drug that is contraindicated or is associated with a dose<br \/>\n      cap for simvastatin, that patient should be switched to an alternative<br \/>\n      statin or statin-based regimen with less potential for the drug-drug<br \/>\n      interaction. Please read Warnings and Precautions in the Prescribing<br \/>\n      Information for additional information.\n    <\/p>\n<p>\n      In addition to drugs that are contraindicated because of an increased<br \/>\n      risk of myopathy\/rhabdomyolysis, grapefruit juice should be avoided. Use<br \/>\n      caution when prescribing VYTORIN with a fenofibrate, and immediately<br \/>\n      discontinue both drugs if myopathy is diagnosed or suspected. Cases of<br \/>\n      myopathy, including rhabdomyolysis, have been reported with simvastatin<br \/>\n      coadministered with colchicine, and caution should be used when<br \/>\n      prescribing VYTORIN with colchicine.\n    <\/p>\n<p>\n      The dose of VYTORIN should not exceed 10\/10 mg daily in patients<br \/>\n      receiving verapamil, diltiazem or dronedarone, and 10\/20 mg daily in<br \/>\n      patients receiving amiodarone, amlodipine or ranolazine. For patients<br \/>\n      with homozygous familial hypercholesterolemia (HoFH) taking lomitapide,<br \/>\n      the dose should not exceed 10\/20 mg\/day (or 10\/40 mg\/day for patients<br \/>\n      who have previously taken simvastatin 80 mg\/day chronically, e.g., for<br \/>\n      12 months or more, without evidence of muscle toxicity); patients<br \/>\n      initiating lomitapide should have their dose of VYTORIN (ezetimibe and<br \/>\n      simvastatin) reduced by 50%. The benefits of combined use of VYTORIN<br \/>\n      with these drugs, other fenofibrates, or niacin (\u22651 g\/day) should be<br \/>\n      carefully weighed against the potential risk of myopathy\/rhabdomyolysis.<br \/>\n      Caution should be used when Chinese patients taking niacin (\u22651 g\/day)<br \/>\n      are coadministered doses of VYTORIN exceeding 10\/20 mg\/day; Chinese<br \/>\n      patients should not receive VYTORIN 10\/80 mg with niacin.\n    <\/p>\n<p>\n      Persistent elevations in hepatic transaminase can occur. Liver function<br \/>\n      tests should be performed at treatment initiation and thereafter when<br \/>\n      clinically indicated. If serious liver injury with clinical symptoms<br \/>\n      and\/or hyperbilirubinemia or jaundice occurs during treatment, therapy<br \/>\n      should be interrupted promptly and not restarted unless an alternate<br \/>\n      etiology is found.\n    <\/p>\n<p>\n      Increases in HbA1c and fasting serum glucose levels have been reported<br \/>\n      with statins, including simvastatin.\n    <\/p>\n<p>\n      In clinical trials, the most commonly reported side effects, regardless<br \/>\n      of cause, included headache (5.8 percent), increased ALT (3.7 percent),<br \/>\n      myalgia (3.6 percent), upper respiratory tract infection (3.6 percent),<br \/>\n      and diarrhea (2.8 percent).\n    <\/p>\n<p>\n      VYTORIN tablets contain ezetimibe and simvastatin: 10 mg of ezetimibe<br \/>\n      and 10, 20, 40, or 80 mg of simvastatin (VYTORIN 10\/10, 10\/20, 10\/40, or<br \/>\n      10\/80 mg, respectively). The usual dosage range is 10\/10 mg\/day to 10\/40<br \/>\n      mg\/day; patients should not be titrated to the restricted 10\/80-mg dose.\n    <\/p>\n<p>\n      <b>About ZETIA (ezetimibe)<\/b>\n    <\/p>\n<p>\n      ZETIA, administered alone or in combination with a statin, is indicated<br \/>\n      as adjunctive therapy to diet for the reduction of elevated total<br \/>\n      cholesterol, LDL cholesterol, apolipoprotein B, and non-HDL cholesterol<br \/>\n      in patients with primary (heterozygous familial and non-familial)<br \/>\n      hyperlipidemia when diet alone is not enough.\n    <\/p>\n<p>\n      The Prescribing Information for ZETIA states that the effect of ZETIA on<br \/>\n      cardiovascular morbidity and mortality has not been determined. ZETIA is<br \/>\n      not indicated for use with a statin to further reduce cardiovascular<br \/>\n      events in patients who have presented with acute coronary syndromes.\n    <\/p>\n<p>\n      <b>Selected cautionary information about ZETIA<\/b>\n    <\/p>\n<p>\n      When using ZETIA with a statin, also follow the label recommendations<br \/>\n      for that specific statin.\n    <\/p>\n<p>\n      When ZETIA was coadministered with a statin, consecutive elevations in<br \/>\n      hepatic transaminase levels (greater than or equal to 3 times ULN) were<br \/>\n      slightly higher (1.3 percent) than those of statins alone (0.4 percent).<br \/>\n      Liver function tests should be performed when ZETIA (ezetimibe) is added<br \/>\n      to statin therapy and according to statin recommendations. Should an<br \/>\n      increase in ALT or AST greater than or equal to 3 times ULN persist,<br \/>\n      consider withdrawal of ZETIA and\/or the statin.\n    <\/p>\n<p>\n      Patients should be advised to promptly report muscle pain, tenderness,<br \/>\n      or weakness. Risk for skeletal muscle toxicity increases with higher<br \/>\n      statin doses, advanced age (&gt;65), hypothyroidism, renal impairment, and<br \/>\n      depending on the statin used, concomitant use of other drugs.<br \/>\n      Discontinue drug if myopathy is diagnosed or suspected.\n    <\/p>\n<p>\n      ZETIA is not recommended in patients with moderate to severe hepatic<br \/>\n      impairment.\n    <\/p>\n<p>\n      The coadministration of ZETIA with fibrates other than fenofibrate is<br \/>\n      not recommended until use in patients is adequately studied. Exercise<br \/>\n      caution when using ZETIA and cyclosporine concomitantly because exposure<br \/>\n      to both drugs is increased. Cyclosporine concentrations should be<br \/>\n      monitored in these patients.\n    <\/p>\n<p>\n      ZETIA should be used in pregnant or nursing women only if the benefit<br \/>\n      outweighs the risk.\n    <\/p>\n<p>\n      In clinical trials, regardless of causality assessment, the most<br \/>\n      frequent side effects for ZETIA coadministered with a statin versus a<br \/>\n      statin alone included nasopharyngitis (3.7 percent vs 3.3 percent),<br \/>\n      myalgia (3.2 percent vs 2.7 percent), upper respiratory tract infection<br \/>\n      (2.9 percent vs 2.8 percent), arthralgia (2.6 percent vs 2.4 percent),<br \/>\n      and diarrhea (2.5 percent vs 2.2 percent); for ZETIA administered alone<br \/>\n      vs placebo: upper respiratory tract infection (4.3 percent vs 2.5<br \/>\n      percent), diarrhea (4.1 percent vs 3.7 percent), arthralgia (3.0 percent<br \/>\n      vs 2.2 percent), sinusitis (2.8 percent vs 2.2 percent), pain in<br \/>\n      extremity (2.7 percent vs 2.5 percent), and fatigue (2.4 percent vs 1.5<br \/>\n      percent).\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51115074&amp;newsitemid=20150603005091&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=c0e774d7e54126488caeb4d75c1c44a4\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><span class=\"bwuline\"><br \/>\n      <\/span>and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.twitter.com%2Fmerck&amp;esheet=51115074&amp;newsitemid=20150603005091&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=413d68bfa550ec4553d48375a61b1674\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2Fmerckbewell&amp;esheet=51115074&amp;newsitemid=20150603005091&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=6600b276bc09317c835bb7fe94e090f0\" rel=\"nofollow\">Facebook<\/a><span class=\"bwuline\"><br \/>\n      <\/span>and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2Fmerck&amp;esheet=51115074&amp;newsitemid=20150603005091&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=0172f19a0d06164c45cad05fe849b9e7\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. If underlying<br \/>\n      assumptions prove inaccurate or risks or uncertainties materialize,<br \/>\n      actual results may differ materially from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2014 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51115074&amp;newsitemid=20150603005091&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=31303757aa72df79075ad1851458a5d7\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for VYTORIN (ezetimibe and<br \/>\n      simvastatin) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvytorin%2Fvytorin_pi.pdf&amp;esheet=51115074&amp;newsitemid=20150603005091&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvytorin%2Fvytorin_pi.pdf&amp;index=8&amp;md5=5d870c260bbbe29a799943e9a522a42e\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/v\/vytorin\/vytorin_pi.pdf<\/b><\/a><br \/>\n      <b>and the Patient Information for VYTORIN at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvytorin%2Fvytorin_ppi.pdf&amp;esheet=51115074&amp;newsitemid=20150603005091&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvytorin%2Fvytorin_ppi.pdf&amp;index=9&amp;md5=68a29b7bc2cf9385fca8777191265264\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/v\/vytorin\/vytorin_ppi.pdf<\/b><\/a>\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for ZETIA (ezetimibe) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzetia%2Fzetia_pi.pdf&amp;esheet=51115074&amp;newsitemid=20150603005091&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzetia%2Fzetia_pi.pdf&amp;index=10&amp;md5=7a6db7d4944df367677fe027d0be34b0\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/z\/zetia\/zetia_pi.pdf<\/b><\/a><b><br \/>\n      and the Patient Information for ZETIA at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzetia%2Fzetia_ppi.pdf&amp;esheet=51115074&amp;newsitemid=20150603005091&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzetia%2Fzetia_ppi.pdf&amp;index=11&amp;md5=17352932d594a423c7d4e894a575ff64\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/z\/zetia\/zetia_ppi.pdf<\/b><\/a>\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150603005091r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><span class=\"bwct31415\" \/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, (267) 305-3558<br \/>Tracy Ogden,        (267) 305-2301<br \/>or<br \/>Investor:<br \/>Justin Holko, (908) 740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK ), known as MSD outside the United States and Canada, today announced that the New England Journal of Medicine published the results of the IMPROVE-IT trial, an investigational study comparing treatment with VYTORIN \u00ae (ezetimibe and simvastatin) to treatment with simvastatin alone in more than 18,000 patients presenting with acute coronary syndromes. The results of IMPROVE-IT were first presented at the American Heart Association Scientific Sessions in November, 2014. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine VYTORIN\u2014 which combines simvastatin with the non-statin ZETIA\u00ae (ezetimibe)\u2014experienced significantly fewer major cardiovascular events (as measured by a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for unstable angina or coronary revascularization occurring at least 30 days after randomization) than patients treated with simvastatin alone. \u201cIMPROVE-IT was designed to answer a<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,55,289],"class_list":["post-745179","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Results from Investigational IMPROVE-IT Study of VYTORIN\u00ae (ezetimibe and simvastatin) Published in the New England Journal of Medicine - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-investigational-improve-it-study-of-vytorin-ezetimibe-and-simvastatin-published-in-the-new-england-journal-of-medicine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Results from Investigational IMPROVE-IT Study of VYTORIN\u00ae (ezetimibe and simvastatin) Published in the New England Journal of Medicine - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK ), known as MSD outside the United States and Canada, today announced that the New England Journal of Medicine published the results of the IMPROVE-IT trial, an investigational study comparing treatment with VYTORIN \u00ae (ezetimibe and simvastatin) to treatment with simvastatin alone in more than 18,000 patients presenting with acute coronary syndromes. The results of IMPROVE-IT were first presented at the American Heart Association Scientific Sessions in November, 2014. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine VYTORIN\u2014 which combines simvastatin with the non-statin ZETIA\u00ae (ezetimibe)\u2014experienced significantly fewer major cardiovascular events (as measured by a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for unstable angina or coronary revascularization occurring at least 30 days after randomization) than patients treated with simvastatin alone. \u201cIMPROVE-IT was designed to answer a\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-investigational-improve-it-study-of-vytorin-ezetimibe-and-simvastatin-published-in-the-new-england-journal-of-medicine\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:07+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150603005091r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-investigational-improve-it-study-of-vytorin-ezetimibe-and-simvastatin-published-in-the-new-england-journal-of-medicine\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-investigational-improve-it-study-of-vytorin-ezetimibe-and-simvastatin-published-in-the-new-england-journal-of-medicine\\\/\",\"name\":\"Results from Investigational IMPROVE-IT Study of VYTORIN\u00ae (ezetimibe and simvastatin) Published in the New England Journal of Medicine - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-investigational-improve-it-study-of-vytorin-ezetimibe-and-simvastatin-published-in-the-new-england-journal-of-medicine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-investigational-improve-it-study-of-vytorin-ezetimibe-and-simvastatin-published-in-the-new-england-journal-of-medicine\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20150603005091r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2015-06-03T16:00:00+00:00\",\"dateModified\":\"2025-11-07T06:25:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-investigational-improve-it-study-of-vytorin-ezetimibe-and-simvastatin-published-in-the-new-england-journal-of-medicine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-investigational-improve-it-study-of-vytorin-ezetimibe-and-simvastatin-published-in-the-new-england-journal-of-medicine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-investigational-improve-it-study-of-vytorin-ezetimibe-and-simvastatin-published-in-the-new-england-journal-of-medicine\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20150603005091r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20150603005091r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-investigational-improve-it-study-of-vytorin-ezetimibe-and-simvastatin-published-in-the-new-england-journal-of-medicine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Results from Investigational IMPROVE-IT Study of VYTORIN\u00ae (ezetimibe and simvastatin) Published in the New England Journal of Medicine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Results from Investigational IMPROVE-IT Study of VYTORIN\u00ae (ezetimibe and simvastatin) Published in the New England Journal of Medicine - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-investigational-improve-it-study-of-vytorin-ezetimibe-and-simvastatin-published-in-the-new-england-journal-of-medicine\/","og_locale":"en_US","og_type":"article","og_title":"Results from Investigational IMPROVE-IT Study of VYTORIN\u00ae (ezetimibe and simvastatin) Published in the New England Journal of Medicine - Merck.com","og_description":"Merck (NYSE: MRK ), known as MSD outside the United States and Canada, today announced that the New England Journal of Medicine published the results of the IMPROVE-IT trial, an investigational study comparing treatment with VYTORIN \u00ae (ezetimibe and simvastatin) to treatment with simvastatin alone in more than 18,000 patients presenting with acute coronary syndromes. The results of IMPROVE-IT were first presented at the American Heart Association Scientific Sessions in November, 2014. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine VYTORIN\u2014 which combines simvastatin with the non-statin ZETIA\u00ae (ezetimibe)\u2014experienced significantly fewer major cardiovascular events (as measured by a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for unstable angina or coronary revascularization occurring at least 30 days after randomization) than patients treated with simvastatin alone. \u201cIMPROVE-IT was designed to answer a","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-investigational-improve-it-study-of-vytorin-ezetimibe-and-simvastatin-published-in-the-new-england-journal-of-medicine\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:07+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150603005091r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-investigational-improve-it-study-of-vytorin-ezetimibe-and-simvastatin-published-in-the-new-england-journal-of-medicine\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-investigational-improve-it-study-of-vytorin-ezetimibe-and-simvastatin-published-in-the-new-england-journal-of-medicine\/","name":"Results from Investigational IMPROVE-IT Study of VYTORIN\u00ae (ezetimibe and simvastatin) Published in the New England Journal of Medicine - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-investigational-improve-it-study-of-vytorin-ezetimibe-and-simvastatin-published-in-the-new-england-journal-of-medicine\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-investigational-improve-it-study-of-vytorin-ezetimibe-and-simvastatin-published-in-the-new-england-journal-of-medicine\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150603005091r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","datePublished":"2015-06-03T16:00:00+00:00","dateModified":"2025-11-07T06:25:07+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-investigational-improve-it-study-of-vytorin-ezetimibe-and-simvastatin-published-in-the-new-england-journal-of-medicine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-investigational-improve-it-study-of-vytorin-ezetimibe-and-simvastatin-published-in-the-new-england-journal-of-medicine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-investigational-improve-it-study-of-vytorin-ezetimibe-and-simvastatin-published-in-the-new-england-journal-of-medicine\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150603005091r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150603005091r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-investigational-improve-it-study-of-vytorin-ezetimibe-and-simvastatin-published-in-the-new-england-journal-of-medicine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Results from Investigational IMPROVE-IT Study of VYTORIN\u00ae (ezetimibe and simvastatin) Published in the New England Journal of Medicine"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"d6a5ebf7-9104-418e-a57f-57b34833a354","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745179","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745179\/revisions"}],"predecessor-version":[{"id":3674631,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745179\/revisions\/3674631"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745179"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745179"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}